Messenger-RNA platforms that encode a patient's neoantigens and are translated into protein in vivo — the modality behind Moderna/Merck's mRNA-4157 and BioNTech's autogene cevumeran.
The nonsense-mediated mRNA decay (NMD) is a highly conserved post-transcriptional mRNA screening system that is vital in keeping cellular integrity by targeting aberrant mRNAs harboring premature termination codons (PTCs) for degradation. Although traditionally considered as a sy…
Personalized mRNA neoantigen vaccines demonstrate great potential in cancer therapy, but their customization typically requires more than three months, risking the loss of the optimal therapeutic window for patients. This delay is primarily due to the reliance of current mRNA vac…
Researchers developed a bivalent mRNA-LNP vaccine targeting AFP and GPC3 neoantigens for hepatocellular carcinoma (HCC). Using spleen-homing CL15H6 LNPs, the formulation achieved superior antigen presentation and co-stimulatory molecule expression on splenic dendritic cells compared to clinical standards. In mouse models, two doses provided complete prophylactic protection against HCC challenge, demonstrating high biosafety and potent cytotoxic T lymphocyte responses.
Personalized neoantigen vaccines are an emerging strategy for cancer immunotherapy, but their effectiveness depends on selecting tumor-specific antigens capable of inducing functional T-cell responses. The VACINUS AI-informed neoantigen prioritization framework previously identif…
The preprint introduces k4neo, a k-mer indexing algorithm that computes tumor specificity of transcript variants by screening against 18,960 healthy tissue samples without mapping or re-analysis. This method addresses the computational cost of verifying tumor-restricted expression for mRNA targets like gene fusions and splice junctions in low-mutational-burden tumors. Benchmarked across nine cohorts, it accurately classifies somatic variants and nominated a median of 4-80 tumor-specific targets per cohort.
West China Hospital has registered a Phase I, single-arm, open-label dose-escalation study for NeoOVIV in stage II/III ovarian cancer patients post-surgery. The personalized mRNA-lipid nanoparticle vaccine will be administered with standard adjuvant chemotherapy and a PD-1 antibody to evaluate safety, tolerability, immunogenicity, and preliminary clinical activity.
Researchers evaluated an individualized neoantigen mRNA vaccine in early-stage TNBC, a subtype with high recurrence risk and no standard targeted therapies. The study demonstrates the feasibility, safety, and immunogenicity of the approach, noting lasting T cell immunity in patients. These findings offer early clinical signals that tailored vaccination may improve long-term outcomes, though larger trials are needed to confirm efficacy.
pVACtools v6 introduces significant updates to its open-source neoantigen prediction suite, including pVACsplice for detecting tumor-specific cis-splicing mutations and pVACbind for noncanonical neoantigen sources. The update also features an improved pVACvector algorithm designed to increase DNA/mRNA vector vaccine design success rates with shorter runtimes. These enhancements address the growing need for robust computational prioritization as neoantigen-based vaccines advance into later-stage trials.
The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine simplywall.st
The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine simplywall.st
Cancer Hospital Chinese Academy of Medical Science has listed a Phase 1 study for RH125, a personalized mRNA tumor vaccine. The trial will evaluate safety, immunogenicity, and preliminary efficacy as monotherapy or combined with a PD-1 blocker in patients with advanced solid tumors who have failed standard treatment.
Shanghai Jiao Tong University School of Medicine is recruiting for a study on mRNA-0523-L001, an individualized mRNA neoantigen vaccine for advanced endocrine tumors. The trial aims to assess safety, tolerability, and preliminary efficacy, including ORR and PFS, in patients with adrenal corticocarcinoma, medullary thyroid carcinoma, and others.
Moderna’s KEYNOTE-942 trial is actively assessing the efficacy of mRNA-4157 combined with pembrolizumab as adjuvant therapy for high-risk melanoma. The study compares recurrence-free survival against pembrolizumab alone in participants who have undergone complete resection.
Yifan Wang is leading a Phase I/II study to evaluate the safety and tolerability of iNeo-Vac-R01, an individualized mRNA therapeutic technology based on tumor neoantigens. The vaccine is intended for the adjuvant treatment of patients with biliary malignant tumors following radical resection.
West China Hospital is recruiting for a Phase 1 study of PAN-NeoVax, an AI-designed pan-cancer neoantigen mRNA vaccine delivered via lipid nanoparticles. Administered intratumorally in patients with advanced solid tumors who have failed second-line therapy, the trial uses a classical 3+3 dose-escalation design to evaluate safety and preliminary anti-tumor efficacy.
Biogenea Pharmaceuticals is recruiting for an early-phase trial of TamavaqTM, an AI-QMMM designed personalized vaccine for newly diagnosed glioma. The study addresses the unmet need in glioblastoma, where no FDA-approved immunotherapies currently exist, by evaluating safety and therapeutic efficacy of DNA, mRNA, or protein-derived neoantigens.
Ruijin Hospital is recruiting for an early-phase trial of XP-004, a personalized mRNA neoantigen vaccine combined with a PD-1 inhibitor as adjuvant therapy for postoperative pancreatic cancer. The study aims to assess safety and preliminary efficacy, including recurrence-free survival, in chemotherapy-intolerant patients following radical resection.
[ACTIVE_NOT_RECRUITING · PHASE3 · Merck Sharp & Dohme LLC] The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents…
Shenzhen Xinhe Biomedical is recruiting for a Phase 1 study evaluating XH001, a personalized mRNA tumor neoantigen vaccine, as adjuvant therapy in high-risk recurrent solid tumors. The trial aims to assess safety and preliminary efficacy, specifically investigating whether the vaccine induces specific T-cell responses and prolongs relapse-free survival when combined with standard adjuvant treatments.
Merck Sharp & Dohme has terminated the Phase 2/3 V940-007 trial evaluating intismeran autogene (V940) plus pembrolizumab in locally resectable advanced cutaneous squamous cell carcinoma. The termination halts the development of this personalized neoantigen therapy in this specific indication, though the parallel Phase 3 melanoma study (NCT05933577) remains active and not yet recruiting.
Yinghua Xu is recruiting for a phase 1/2 trial of iNeo-Vac-R01, a personalized mRNA neoantigen therapy, in combination with a PD-1 inhibitor for adjuvant treatment of liver cancer post-radical resection. The study aims to assess safety and preliminary efficacy to improve disease-free and overall survival.
A review of mRNA vaccines in gastrointestinal cancers highlights their rapid, cell-free manufacturing and modular design as key advantages over conventional platforms. However, efficacy is constrained by tumor heterogeneity and immunosuppressive microenvironments, with antigen selection strategies for personalized neoantigens remaining a critical variable for immune specificity and therapeutic variability.
Interim results from a Phase 1 trial of an individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine show activity in advanced metastatic solid tumors. This highlights the diversification of delivery vectors beyond standard mRNA, potentially offering improved immunogenicity or manufacturing advantages.
Moderna’s individualized neoantigen therapy demonstrated broad efficacy in cancer treatment at ASCO2024. As a leading platform player, Moderna’s positive data reinforces investor confidence in the scalability and clinical utility of mRNA-based personalized vaccines across diverse tumor types.
Shenzhen Xinhe Biomedical has initiated a Phase 1 trial for XH001, a personalized mRNA tumor neoantigen vaccine, as adjuvant therapy for high-risk recurrent solid tumors. This entry marks the expansion of Chinese biotech players into the personalized vaccine space, focusing on post-surgical recurrence prevention.
Researchers present PimRNA, a computational framework that prioritizes personalized mRNA vaccines by integrating neoantigen identification with gene interaction network analysis. This addresses a key translational gap by moving beyond simple HLA binding affinity to consider biological context and mRNA design constraints like codon usage.
EurekAlert reports on how neoantigen dendritic cell vaccines are reshaping immunotherapy. This highlights the diversification of vaccine modalities, with dendritic cell-based approaches offering an alternative mechanism to mRNA/DNA vaccines for antigen presentation.
Shanghai Jiao Tong University School of Medicine is recruiting for a trial of mRNA-0523-L001, an individualized mRNA neoantigen vaccine, in advanced endocrine tumors including adrenal corticocarcinoma and medullary thyroid carcinoma. The study evaluates safety, tolerability, and preliminary efficacy, including T-cell responses and objective response rates, in patients with failed or no standard treatments.
Yifan Wang is leading a Phase I/II trial for iNeo-Vac-R01, an individualized mRNA therapeutic based on tumor neoantigens. The study evaluates safety for adjuvant treatment in patients with biliary malignant tumors after radical resection, marking a move toward mRNA-based personalization in hepatobiliary cancers.
West China Hospital has launched a Phase I dose-escalation study for PAN-NeoVax, an AI-designed pan-cancer neoantigen mRNA vaccine delivered via intratumoral injection. The trial targets advanced solid tumors post-second-line therapy, utilizing a 3+3 design to assess safety and preliminary efficacy of lipid nanoparticle-formulated mRNA.
A comprehensive review in EuropePMC synthesizes the current state of neoantigen-based T cell vaccines, covering design strategies, therapeutic barriers, and clinical advances. The article examines mechanisms across mRNA, peptide, and dendritic cell platforms, highlighting synergies with checkpoint blockade and the challenges of immunosuppressive tumor microenvironments.